Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.
Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM
J Alzheimers Dis. 2018; 66(3)1213-1221. doi: 10.3233/JAD-180564.

PMID:
    30400098
    [PubMed - in process]
Related citations


High-affinity interactions and signal transduction between Aβ oligomers and TREM2.
Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE
EMBO Mol Med. 2018 Nov; 10(11)pii: e9027. doi: 10.15252/emmm.201809027.

PMID:
    30341064
    [PubMed - in process]
Related citations


Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV
Mol Neurodegener. 2018 Oct 19; 13(1)57. doi: 10.1186/s13024-018-0286-0.

PMID:
    30340601
    [PubMed - in process]
Related citations


Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.
Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC
Brain. 2018 Nov 1; 141(11)3233-3248. doi: 10.1093/brain/awy244.

PMID:
    30304397
    [PubMed - in process]
Related citations


Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ, Dominantly Inherited Alzheimer Network.
Neurology. 2018 Oct 2; 91(14)e1295-e1306. doi: 10.1212/WNL.0000000000006277.

PMID:
    30217935
    [PubMed - in process]
Related citations


Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.
Shi Y, Holtzman DM
Nat Rev Immunol. 2018 Dec; 18(12)759-772. doi: 10.1038/s41577-018-0051-1.

PMID:
    30140051
    [PubMed - in process]
Related citations


In Search of an Identity for Amyloid Plaques.
Huynh TV, Holtzman DM
Trends Neurosci. 2018 Aug; 41(8)483-486. doi: 10.1016/j.tins.2018.06.002.

PMID:
    30053949
    [PubMed - in process]
Related citations


Intercellular Spread of Protein Aggregates in Neurodegenerative Disease.
Davis AA, Leyns CEG, Holtzman DM
Annu Rev Cell Dev Biol. 2018 Oct 6; 34545-568. doi: 10.1146/annurev-cellbio-100617-062636.

PMID:
    30044648
    [PubMed - in process]
Related citations


Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP.
Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, Chávez-Gutiérrez L, Cleverley K, Noy S, Sheppard O, Collins T, Powell C, Sarell CJ, Rickman M, Choong X, Tosh JL, Siganporia C, Whittaker HT, Stewart F, Szaruga M, London Down syndrome consortium ., Murphy MP, Blennow K, de Strooper B, Zetterberg H, Bannerman D, Holtzman DM, Tybulewicz VLJ, Fisher EMC
Brain. 2018 Jun 26; doi: 10.1093/brain/awy159.

PMID:
    29945247
    [PubMed - as supplied by publisher]
Related citations


Using the A/T/N Framework to Examine Driving in Preclinical AD.
Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC
Geriatrics (Basel). 2018 Jun; 3(2)pii: 23. doi: 10.3390/geriatrics3020023.

PMID:
    29805967
    [PubMed]
Related citations


AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
Hettinger JC, Lee H, Bu G, Holtzman DM, Cirrito JR
Mol Neurodegener. 2018 May 15; 13(1)22. doi: 10.1186/s13024-018-0256-6.

PMID:
    29764453
    [PubMed - indexed for MEDLINE]
Related citations


White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.
Lee S, Zimmerman ME, Narkhede A, Nasrabady SE, Tosto G, Meier IB, Benzinger TLS, Marcus DS, Fagan AM, Fox NC, Cairns NJ, Holtzman DM, Buckles V, Ghetti B, McDade E, Martins RN, Saykin AJ, Masters CL, Ringman JM, Fӧrster S, Schofield PR, Sperling RA, Johnson KA, Chhatwal JP, Salloway S, Correia S, Jack CR Jr, Weiner M, Bateman RJ, Morris JC, Mayeux R, Brickman AM, Dominantly Inherited Alzheimer Network.
PLoS One. 2018; 13(5)e0195838. doi: 10.1371/journal.pone.0195838.

PMID:
    29742105
    [PubMed - indexed for MEDLINE]
Related citations


Dual therapy for Aβ amyloidosis in AD: A successful one-two combo.
Patel TK, Holtzman DM
J Exp Med. 2018 May 7; 215(5)1267-1268. doi: 10.1084/jem.20180494.

PMID:
    29685951
    [PubMed - in process]
Related citations


Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype.
Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA
Brain. 2018 Jun 1; 141(6)1828-1839. doi: 10.1093/brain/awy103.

PMID:
    29672664
    [PubMed - in process]
Related citations


NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors.
Alzheimers Dement. 2018 Apr; 14(4)535-562. doi: 10.1016/j.jalz.2018.02.018.

PMID:
    29653606
    [PubMed - in process]
Related citations


Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.
Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, Finn MB, Hoyle R, Keyser J, Lefton KB, Robinson GO, Serrano JR, Silverman AP, Guo JL, Getz J, Henne K, Leyns CE, Gallardo G, Ulrich JD, Sullivan PM, Lerner EP, Hudry E, Sweeney ZK, Dennis MS, Hyman BT, Watts RJ, Holtzman DM
J Clin Invest. 2018 May 1; 128(5)2144-2155. doi: 10.1172/JCI96429.

PMID:
    29600961
    [PubMed - in process]
Related citations


Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease.
Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, Fagan AM, ADNI.
Alzheimers Dement. 2018 Jul; 14(7)869-879. doi: 10.1016/j.jalz.2018.01.012.

PMID:
    29580670
    [PubMed - in process]
Related citations


Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.
Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, Wahl S, Benzinger TLS, Holtzman DM, Morris JC, Fagan AM
Alzheimers Dement. 2018 Nov; 14(11)1460-1469. doi: 10.1016/j.jalz.2018.01.013.

PMID:
    29501462
    [PubMed - in process]
Related citations


ApoE facilitates the microglial response to amyloid plaque pathology.
Ulrich JD, Ulland TK, Mahan TE, Nyström S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM
J Exp Med. 2018 Apr 2; 215(4)1047-1058. doi: 10.1084/jem.20171265.

PMID:
    29483128
    [PubMed - in process]
Related citations


Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Förster S, Fox NC, Graff-Radford NR, la Fougère C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS
Lancet Neurol. 2018 Mar; 17(3)241-250. doi: 10.1016/S1474-4422(18)30028-0.

PMID:
    29397305
    [PubMed - in process]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: C2N Diagnostics

Royalties: > $250,000

Equity: Yes

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2018


Company Name: Denali

Royalties: $1 - $9,999

Equity: No

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2018

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.